Concourse Financial Group Securities, Inc. Lucid Diagnostics Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.67 Billion
Q4 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share
Q4 2024 Feb 13, 2025	BUY	$0.76 - $1.08 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$0.75 - $0.88 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$0.67 - $1.04 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$0.81 - $1.52 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$1.16 - $1.54 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.17 - $1.65 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.17 - $1.65 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.28 - $1.78 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.17 - $1.77 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.21 - $2.27 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.53 - $3.45 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.73 - $3.44 $0 - $0
Q1 2022 May 09, 2022	BUY	$2.85 - $5.24 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$4.87 - $11.76 $0 - $0

Others Institutions Holding LUCD

# of Institutions

Shares Held

3.39M

Call Options Held

Put Options Held

View Full List

About Lucid Diagnostics Inc.

Ticker LUCD
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 38,568,500
Market Cap $58.6M
Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...

More about LUCD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account